Stem cell therapy benefits patients with severe inflammation, trial data show
from COPD News Today
Remestemcel-L, Mesoblast’s lead candidate stem cell therapy for inflammatory diseases, improves lung function and exercise capacity in people with chronic obstructive pulmonary disease and a high degree of inflammation, data from a post-hoc analysis of a Phase 2 trial show.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063